Its lead asset, zolucatetide (FOG-001), is a first-in-class, clinically validated direct inhibitor of the interaction between ß-catenin and the T-cell factor (TCF) family of transcription factors, implicated in millions of cancer cases annually, including in colorectal cancer, desmoid tumors, hepatocellular carcinoma and a range of other Wnt/ß-catenin-driven tumors. This role focuses on the program management of late-stage Discovery programs, those in the final stretch toward development candidate (DC) nomination, ensuring that cross-functional teams move with urgency, alignment, and scientific rigor, and that programs transition smoothly into the Development function.